Company profile
OPKO HEALTH, INC.
NASDAQ:OPKBiotechnology: Pharmaceutical Preparations
Drug pipeline (5)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| SOMATROGON | phase3 | — | 9 | completed, terminated |
| LUNACALCIPOL | phase2 | — | 2 | no active trials |
| PEGAPAMODUTIDE | phase2 | — | 2 | completed, terminated |
| SCYLLO-INOSITOL | phase2 | — | 5 | completed, terminated |
| TT-301 | phase1 | — | 1 | no active trials |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (53)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01766336 | phase2 | terminated | 2013-01-01 | 2015-08-01 | OPKO Health, Inc. | A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease |
| NCT01791725 | phase2 | completed | 2013-09-01 | 2014-06-01 | OPKO Health, Inc. | A 4-Week Safety Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia |
| NCT03810664 | phase1 | completed | 2019-01-18 | 2019-04-19 | OPKO Health, Inc. | A Clinical Study Investigating the Comparability of Somatrogon in Two Different Drug Product Presentations |
| NCT01909479 | phase3 | terminated | 2013-06-01 | 2016-08-01 | OPKO Health, Inc. | A Phase 3, Multicenter Study To Evaluate The Efficacy And Safety Of MOD-4023 In Adults With Growth Hormone Deficiency |
| NCT02919800 | phase1 | completed | 2017-01-22 | 2018-02-21 | OPKO Health, Inc. | A Single-dose, Dose-escalation Study of a Long-acting MOD-5014 in Healthy Adult Male |
FDA applications (0)
No records yet.